Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bay Area Biotech, J&J Ink IBS Deal

J&J subsidiary Janssen inked a collaboration deal to develop Protagonist Therapeutics’ PTG-200 for various gastrointestinal diseases.

Read More »

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

U.S. drugmaker Pfizer Inc. reached an agreement with Sangamo Therapeutics Inc. for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A.

Read More »

Amgen Eying Two Biotechs’ Shark Antibodies

Amgen may need a bigger boat. The company is eying the use of shark-inspired antibodies called soloMERs to go after two undisclosed intracellular targets.

Read More »

Immunomedics CEO, COO Exit

Immunomedics’ chief executive office and chief scientific officer will step down. Also, Seattle Genetics backed out of a $2 billion deal with the company.

Read More »

Allergan signs deal with Editas for gene-editing-based eye treatments

Allergan plc said it would get exclusive access and the option to license up to five of Editas Medicine Inc.’s experimental gene-editing-based eye treatments under a research and development deal between the two companies.

Read More »

Sanofi Pasteur Inks $645 Million RSV Deal With AstraZeneca’s MedImmune

Paris-based Sanofi Pasteur announced that it had inked a development agreement with MedImmune, the research-and-development art of AstraZeneca.

Read More »

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016

For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.

Read More »

Immunomedics, Seattle Genetics ink $2 billion deal

Drug developer Immunomedics Inc. entered into a development and licensing deal worth up to $2 billion for its experimental cancer drug with Seattle Genetics Inc.

Read More »

Actelion drug setback unlikely to derail J&J talks

A blow to Actelion’s Opsumit drug in a test is unlikely to have an impact on talks over a strategic deal with Johnson & Johnson, analysts said.

Read More »

Merck KGaA Licenses 4 Oncology R&D Programs

Merck KGaA entered into a licensing deal with Vertex Pharmaceuticals for the worldwide development and commercialization of four promising R&D programs.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom